Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

about

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

Item

http://www.wikidata.org/entity/Q57067866

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Ten years of sorafenib in hepa ...... ive and/or prognostic markers?

@en

Ten years of sorafenib in hepa ...... ive and/or prognostic markers?

@nl

type

Item

label

Ten years of sorafenib in hepa ...... ive and/or prognostic markers?

@en

Ten years of sorafenib in hepa ...... ive and/or prognostic markers?

@nl

prefLabel

Ten years of sorafenib in hepa ...... ive and/or prognostic markers?

@en

Ten years of sorafenib in hepa ...... ive and/or prognostic markers?

@nl

P1476

Ten years of sorafenib in hepa ...... ive and/or prognostic markers?

@en

P2093

Alessandro Cucchetti

http://www.w3.org/2001/XMLSchema#string

Francesco G Foschi

http://www.w3.org/2001/XMLSchema#string

Giorgia Marisi

http://www.w3.org/2001/XMLSchema#string

Giorgio Ercolani

http://www.w3.org/2001/XMLSchema#string

Giovanni L Frassineti

http://www.w3.org/2001/XMLSchema#string

Giuseppe Cabibbo

http://www.w3.org/2001/XMLSchema#string

Leonardo Solaini

http://www.w3.org/2001/XMLSchema#string

Mario Scartozzi

http://www.w3.org/2001/XMLSchema#string

Martina Valgiusti

http://www.w3.org/2001/XMLSchema#string

Matteo Canale

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Hepatocellular carcinoma

Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.

Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.

Angiopoietin-2: development of inhibitors for cancer therapy.

Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.

P304

4152-4163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.3748/WJG.V24.I36.4152

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Casadei Gardini

P5008

ScienceSource

P577

2018-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30271080

http://www.w3.org/2001/XMLSchema#string

P921

hepatocellular carcinoma

P932

6158485

http://www.w3.org/2001/XMLSchema#string